New drugs to watch
There are over 500 new anti-cancer drugs in various stages of clinical development. The BJC remains an important venue to report clinical trial results. The following is a brief selection of recently published trials with promising new drugs to watch.
A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies Open
C-C Lin, W-C Su, C-J Yen, C-H Hsu, W-P Su, K-H Yeh, Y-S Lu, A-L Cheng, D C-L Huang, H Fritsch, F Voss, T Taube and J C-H Yang
British Journal of Cancer 110: 2434-2440; Published online, 22 April 2014; doi:10.1038/bjc.2014.195
A phase I study of the combination of ro4929097 and cediranib in patients with advanced solid tumours (PJC-004/NCI 8503) Open
S Sahebjam, P L Bedard, V Castonguay, Z Chen, M Reedijk, G Liu, B Cohen, W-J Zhang, B Clarke, T Zhang, S Kamel-Reid, H Chen, S P Ivy, A R A Razak, A M Oza, E X Chen, H W Hirte, A McGarrity, L Wang, L L Siu and S J Hotte
British Journal of Cancer 109: 943-949; Published online, 18 July 2013; doi:10.1038/bjc.2013.380
First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer Open
D Bianchini, A Omlin, C Pezaro, D Lorente, R Ferraldeschi, D Mukherji, M Crespo, I Figueiredo, S Miranda, R Riisnaes, A Zivi, A Buchbinder, D E Rathkopf, G Attard, H I Scher, J de Bono and D C Danila
British Journal of Cancer 109: 2579-2586; Published online, 29 October 2013; doi:10.1038/bjc.2013.619
CYP2C19 genotype-based phase I studies of a c-Met inhibitor tivantinib in combination with erlotinib, in advanced/metastatic non-small cell lung cancer Open
N Yamamoto, H Murakami, H Hayashi, Y Fujisaka, T Hirashima, K Takeda, M Satouchi, K Miyoshi, S Akinaga, T Takahashi and K Nakagawa
British Journal of Cancer 109: 2803-2809; Published online, 29 October 2013; doi:10.1038/bjc.2013.588
Phase I–II study of plitidepsin and dacarbazine as first-line therapy for advanced melanoma Open
R Plummer, P Lorigan, E Brown, R Zaucha, V Moiseyenko, L Demidov, V Soriano, E Chmielowska, R Andrés, G Kudryavtseva, C Kahatt, S Szyldergemajn, S Extremera, B de Miguel, M Cullell-Young and H Calvert
British Journal of Cancer 109: 1451-1459; Published online, 29 August 2013; doi:10.1038/bjc.2013.477
Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib Open
Y-K Kang, C Yoo, B-Y Ryoo, J J Lee, E Tan, I Park, J H Park, Y J Choi, J Jo, J-S Ryu and M-H Ryu
British Journal of Cancer 109: 2309-2315; Published online, 01 October 2013; doi:10.1038/bjc.2013.594
Phase II study of pazopanib monotherapy in metastatic gastroenteropancreatic neuroendocrine tumours Open
H K Ahn, J Y Choi, K-M Kim, H Kim, S-H Choi, S H Park, J O Park, H Y Lim, W K Kang, J Lee and Y S Park
British Journal of Cancer 109: 1414-1419; Published online, 29 August 2013; doi:10.1038/bjc.2013.470
Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma Open
A Naing, P LoRusso, S Fu, D Hong, H X Chen, L A Doyle, A T Phan, M A Habra and R Kurzrock
British Journal of Cancer 108: 826-830; Published online, 14 February 2013; doi:10.1038/bjc.2013.46
Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial Open
N Colombo, D S McMeekin, P E Schwartz, C Sessa, P A Gehrig, R Holloway, P Braly, D Matei, A Morosky, P F Dodion, M H Einstein and F Haluska
British Journal of Cancer 108: 1021-1026; Published online, 12 February 2013; doi:10.1038/bjc.2013.59
A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis Open
A Santoro, M Simonelli, C Rodriguez-Lope, P Zucali, L H Camacho, A Granito, N Senzer, L Rimassa, G Abbadessa, B Schwartz, M Lamar, R E Savage and J Bruix
British Journal of Cancer 108: 21-24; Published online, 03 January 2013; doi:10.1038/bjc.2012.556
Combination neratinib (HKI-272) and paclitaxel therapy in patients with HER2-positive metastatic breast cancer Open
L W-C Chow, B Xu, S Gupta, A Freyman, Y Zhao, R Abbas, M-L Vo Van and I Bondarenko
British Journal of Cancer 108: 1985-1993; Published online, 30 April 2013; doi:10.1038/bjc.2013.178
Phase I clinical trial of human vascular endothelial growth factor receptor 1 peptide vaccines for patients with metastatic renal cell carcinoma Open
K Yoshimura, T Minami, M Nozawa and H Uemura
British Journal of Cancer 108: 1260-1266; Published online, 07 March 2013; doi:10.1038/bjc.2013.90
Phase I study of tremelimumab (CP-675 206) plus PF-3512676 (CPG 7909) in patients with melanoma or advanced solid tumours Open
M Millward, C Underhill, S Lobb, J McBurnie, S J Meech, J Gomez-Navarro, M A Marshall, B Huang and C B Mather
British Journal of Cancer 108: 1998-2004; Published online, 07 May 2013; doi:10.1038/bjc.2013.227
A first-in-class, first-in-human, phase I trial of p28, a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in patients with advanced solid tumours Open
M A Warso, J M Richards, D Mehta, K Christov, C Schaeffer, L Rae Bressler, T Yamada, D Majumdar, S A Kennedy, C W Beattie and T K Das Gupta
British Journal of Cancer 108: 1061-1070; Published online, 28 February 2013; doi:10.1038/bjc.2013.74
partner of